# TOPical Sirolimus in linGUal Microcystic Lymphatic Malformation -TOPGUN

> **NCT04128722** · PHASE2 · COMPLETED · sponsor: **University Hospital, Tours** · enrollment: 12 (actual)

## Conditions studied

- Lingual Microcystic Lymphatic Malformations

## Interventions

- **DRUG:** Sirolimus Oral Liquid Product 1mg/mL

## Key facts

- **NCT ID:** NCT04128722
- **Lead sponsor:** University Hospital, Tours
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-02-14
- **Primary completion:** 2025-01-08
- **Final completion:** 2025-01-08
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2025-11-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04128722

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04128722, "TOPical Sirolimus in linGUal Microcystic Lymphatic Malformation -TOPGUN". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT04128722. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*